BLBryan H. Louie

Bryan H. Louie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bryan H. Louie has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Hyo Jeong Lim

    Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea

    3 shared publications
  • Ki Hwan Kim

    Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    3 shared publications
  • Razelle Kurzrock

    WIN Consortium for Precision Medicine, Paris, France

    3 shared publications
  • Howard Y. Chang

    Departments of Dermatology, Genetics, and Pathology, Stanford University School of Medicine, Stanford, USA

    2 shared publications
  • Jeffrey M. Granja

    Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA

    2 shared publications
  • Maxwell R. Mumbach

    Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA

    2 shared publications

Latest Publications

  • Open Access

    Initial Experience with Robotic-Assisted CT-Guided Ablation: Analysis from a Single Center’s Learning Curve in the First 54 Patients

    by Zachary T. Berman, Bryan Louie, Jeet Minocha, Jonas Redmond, Anthony Tadros, John York, Sean Tutton


  • Open Access

    Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

    by Bryan H. Louie, Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Lisa Kim, Jason K. Sicklick, Scott M. Lippman, et al.


  • Open Access

    Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

    by Bryan H. Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander, Gregory Botta, Hitendra Patel, Suzanna Lee, Scott M. Lippman, et al.

    Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics to develop N-of-One therapies for patients in the pan-cancer, advanced, refractory setting. This study evaluates the experience of 80 patients who were presented to the MTB and received a treatment regimen that included ICB. Overall, 60/80 patients (75%) who received ICB following MTB discussion had a high degree of matching between tumor molecular characteristics, including ICB biomarkers (reflected by a high Matching Score (≥50%)) and therapy administered. Patients with high versus low Matching Score experienced significantly longer median progression-free survival (6.4 vs. 3.0 months; p = 0.011) and median overall survival (15.3 vs. 4.7 months; p = 0.014) and higher clinical benefit rates (stable disease ≥6 months/partial response/complete response) (53% vs. 21%, p = 0.019). Although most patients (52/80 (65%)) received a personalized combination therapy (e.g., targeted, hormonal, chemotherapy, or a second immunotherapy agent), administering >1 drug was not associated with outcome. Only degree of matching and age, but no other variables, including individual biomarkers (e.g., microsatellite status, tumor mutational burden, or PD-L1 status), were independently correlated with outcome. In the pan-cancer setting, the MTB facilitated a precision medicine strategy to match therapeutic regimens that included ICB alone or combined with matched targeted drugs to patients with advanced malignancy, which was associated with improved clinical outcomes.


  • Open Access

    Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience

    by Bryan H. Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Suzanna Lee, Ryosuke Okamura, Paul T. Fanta, Razelle Kurzrock

    Treatment for advanced colorectal cancer is often limited by complex molecular profiles, which promote resistance to systemic agents and targeted monotherapies. Recent studies suggest that a personalized, combinatorial approach of matching drugs to tumor alterations may be more effective. We implemented a precision medicine strategy by forming a Molecular Tumor Board (MTB), a multidisciplinary team of clinicians, scientists, bioinformaticians and geneticists. The MTB integrated molecular profiling information and patient characteristics to develop N‐of‐One treatments for 51 patients with advanced colorectal cancer. All patients had metastatic disease and 63% had received ≥ 3 prior therapy lines. Overall, 34/51 patients (67%) were matched to ≥ 1 drug recommended by the MTB based on individual tumor characteristics, whereas 17/51 (33%) patients received unmatched therapies. Patients who received matched therapy demonstrated significantly longer progression‐free survival (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21–0.81;P = 0.01) and a trend towards higher clinical benefit rates (41% vs. 18%,P = 0.058) (all multivariate) compared to patients receiving unmatched therapy. The MTB facilitated personalized matching of drugs to tumor characteristics, which was associated with improved progression‐free survival in patients with advanced colorectal cancer.


  • Top Cited Papers
    Open Access

    BAP1: Not just a BRCA1-associated protein

    by Bryan H. Louie, Razelle Kurzrock


  • HiChIRP reveals RNA-associated chromosome conformation

    by Maxwell R. Mumbach, Jeffrey M. Granja, Ryan A. Flynn, Caitlin M. Roake, Ansuman T. Satpathy, Adam J. Rubin, Yanyan Qi, Zhaozhao Jiang, Shadi Shams, Bryan H. Louie, et al.

    Modular domains of long non-coding RNAs can serve as scaffolds to bring distant regions of the linear genome into spatial proximity. Here, we present HiChIRP, a method leveraging bio-orthogonal chemistry and optimized chromosome conformation capture conditions, which enables interrogation of chromatin architecture focused around a specific RNA of interest down to approximately ten copies per cell. HiChIRP of three nuclear RNAs reveals insights into promoter interactions (7SK), telomere biology (telomerase RNA component) and inflammatory gene regulation (lincRNA-EPS).


  • Top Cited Papers

    The chromatin accessibility landscape of primary human cancers

    by M. Ryan Corces, Jeffrey M. Granja, Shadi Shams, Bryan H. Louie, Jose A. Seoane, Wanding Zhou, Tiago C. Silva, Clarice Groeneveld, Christopher K. Wong, Seung Woo Cho, et al.

    Cancer chromatin accessibility landscape: The Cancer Genome Atlas (TCGA) provides a high-quality resource of molecular data on a large variety of human cancers. Corces et al. used a recently modified assay to profile chromatin accessibility to determine the accessible chromatin landscape in 410 TCGA samples from 23 cancer types (see the Perspective by Taipale). When the data were integrated with other omics data available for the same tumor samples, inherited risk loci for cancer predisposition were revealed, transcription factors and enhancers driving molecular subtypes of cancer with patient survival differences were identified, and noncoding mutations associated with clinical prognosis were discovered. Science , this issue p. eaav1898 ; see also p. 401